Search results
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
FOX 23 News Albany· 3 days agoNotable data include an oral presentation on biomarker analyses from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial (NCT02811861), which evaluated lenvatinib (LENVIMA®), the orally ...
Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at...
WKBN 27 Youngstown· 3 days agoOn May 10, 2024, Cure Genetics announced the safety and efficacy data of their CAR-NKT product, CGC729, for patients with relapsed and refractory metastatic renal
Kidney Cancer Immunotherapy Response Linked to Signature Reflecting HLA, Tumor Immune Activity
GenomeWeb News· 5 days agoResearchers found an immune checkpoint blockade response signature in renal cell carcinoma that reflects tumor immune activity influenced by human leukocyte antigen features.
Director Julie Smith Sells 27,280 Shares of Exelixis Inc (EXEL)
GuruFocus.com via Yahoo Finance· 3 days agoExelixis Inc is a biotechnology company focused on the discovery, development, and commercialization...
Ipilimumab, a Pioneer Breakthrough in Cancer Treatment
Forbes· 7 days agoIn 2011, the first in a new generation of anticancer drugs called checkpoint inhibitors was...
Rutgers Cancer Institute and RWJBarnabas Health Se | Newswise
Newswise· 4 days agoClinicians and scientists from Rutgers Cancer Institute and RWJBarnabas Health will lead sessions...
Nimbus reports positive data from Phase I/II solid tumour therapy trial
Clinical Trials Arena via Yahoo Finance· 3 days agoAccording to the results, 16.7% of response-evaluable patients experienced clinical benefits from...
Get Ready for ASCO 2024 Annual Meeting | Newswise
Newswise· 5 days agoASCO, the largest event in cancer research, is approaching on May 31st. This year's meeting promises to be particularly groundbreaking, with new findings a
Tumor mutations may not predict response to immunotherapy, study finds
Medical Xpress· 3 days agoThe findings, published in Nature Cancer, upend long-held conventional wisdom and could lead to more effective ways of deciding which patients will benefit most from this type of treatment ...
Assetmark Inc. Boosts Stock Position in BeiGene, Ltd. (NASDAQ:BGNE)
ETF DAILY NEWS· 15 hours agoAssetmark Inc. boosted its holdings in shares of BeiGene, Ltd. (NASDAQ:BGNE – Free Report) by 13.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange ...